i think when cu64 gets commercialised is up in the air until we see how quickly amplify recruits. 220 patients for a multi centre trial hopefully shouldn't take too long. If ATs aspirations are correct and it finishes end of yr, potentially this could be approved end of 26. With that said AT was far too aspirational before with prior timelines, so we shall see. But even if amplify finishes recruitment in 2026, commercialisation would be late 2027. 2028 commercialisation seem very conservative, but I think their poor communication has aided in this.
CU6 Price at posting:
$1.90 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)